Nature Medicine, Published online: 14 August 2025; doi:10.1038/s41591-025-03875-5
In cohort B of the phase 2 SWOG S1512 trial, pembrolizumab monotherapy in patients with unresectable desmoplastic melanoma elicited a complete response rate of 37% and an objective response rate of 89%, supporting a new treatment option for this tumor type.
